| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
159,210,000 |
| Market
Cap: |
1.08(B) |
| Last
Volume: |
2,204,422 |
Avg
Vol: |
2,198,299 |
| 52
Week Range: |
$1.78 - $6.34 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hsu Larry |
Director |
• • – |
2014-06-05 |
4 |
S |
$28.25 |
$1,412,470 |
D/D |
(50,000) |
359,568 |
|
- |
|
| Terreri Peter R |
Director |
• • – |
2014-05-27 |
4 |
AS |
$28.00 |
$84,000 |
D/D |
(3,000) |
41,520 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. |
• • – |
2014-05-26 |
4 |
D |
$27.89 |
$34,082 |
D/D |
(1,222) |
106,466 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• • – |
2014-05-23 |
4 |
D |
$27.89 |
$22,730 |
D/D |
(815) |
78,024 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. |
• • – |
2014-05-23 |
4 |
D |
$27.89 |
$34,082 |
D/D |
(1,222) |
107,688 |
|
- |
|
| Hsu Larry |
Director |
• • – |
2014-05-22 |
4 |
S |
$27.22 |
$1,360,835 |
D/D |
(50,000) |
409,568 |
|
- |
|
| Hsu Larry |
Director |
• • – |
2014-05-21 |
4 |
S |
$26.53 |
$100,827 |
D/D |
(3,800) |
459,568 |
|
- |
|
| Terreri Peter R |
Director |
• • – |
2014-05-20 |
4 |
AS |
$26.07 |
$17,363 |
D/D |
(666) |
44,520 |
|
- |
|
| Terreri Peter R |
Director |
• • – |
2014-05-19 |
4 |
AS |
$26.03 |
$24,729 |
D/D |
(950) |
45,186 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2014-05-16 |
4 |
S |
$25.72 |
$48,868 |
D/D |
(1,900) |
11,266 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• • – |
2014-05-15 |
4 |
D |
$25.56 |
$59,555 |
D/D |
(2,330) |
78,839 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. |
• • – |
2014-05-15 |
4 |
D |
$25.56 |
$3,732 |
D/D |
(146) |
108,910 |
|
- |
|
| Reasons Bryan M. |
Chief Financial Officer |
• • – |
2014-05-15 |
4 |
D |
$25.56 |
$35,784 |
D/D |
(1,400) |
55,686 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
23,000 |
81,169 |
|
- |
|
| Ben-Maimon Carole |
President, Global Pharm. |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
23,000 |
85,914 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
23,000 |
109,056 |
|
- |
|
| Reasons Bryan M. |
Chief Financial Officer |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
23,000 |
57,086 |
|
- |
|
| Nornhold Jeffrey |
SVP, Technical Operations |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,565 |
65,640 |
|
- |
|
| Markbreiter Michael |
Director |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
14,499 |
|
- |
|
| Terreri Peter R |
Director |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
46,136 |
|
- |
|
| Pendergast Mary K |
Director |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
10,500 |
|
- |
|
| Hsu Larry |
Director |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
463,368 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
13,166 |
|
- |
|
| Chao Allen |
Director |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
57,595 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2014-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
48,625 |
|
- |
|
215 Records found
|
|
Page 8 of 9 |
|
|
0.55 (8.86%) 
